Bahija Jallal, Immunocore CEO
July 18, 2022 11:03 AM EDT
Financing

Im­muno­core is the lat­est to nab a pri­vate place­ment, se­cur­ing $140M to pur­sue more TCR R&D

Paul Schloesser

Associate Editor

Look­ing to se­cure a fresh raise to in­vig­o­rate R&D, Im­muno­core is putting to­geth­er a PIPE.

The for­mer Medi­gene spin­out, six months af­ter the FDA ap­proved …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

Jim Wilson's Gem­ma­Bio rais­es $34M to com­mer­cial­ize gene ther­a­pies for rare dis­eases

A service from the Financial Times